Work

A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of PLX9486 alone and in combination (combo) with the KIT inhibitors pexidartinib (pexi) or sunitinib (su) in patients (Pts) with advanced solid tumors and gastrointestinal stromal tumor (GIST).

Year: 2018

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2018.36.15_suppl.11509

Authors: Andrew J. Wagner, William D. Tap, Anthony Frank Shields, Amita Patnaik, Rashmi Chugh, Gabriel Tinoco, Glenn Michelson, Oscar Alcantar, Michael Pelayo, Chao Zhang, Paul Severson, Eric Martin, Jonathan C. Trent

Institutions: Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, Wayne State University, The Barbara Ann Karmanos Cancer Institute, South Texas Accelerated Research Therapeutics, University of Michigan, The Ohio State University, Plexxikon (United States), Sylvester Comprehensive Cancer Center

Language: English

Topic: Gastrointestinal Tumor Research and Treatment

Subfield: Gastroenterology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2891111363

Cites:

Cited by: 9

Related to: 10